Business Wire

BEHAVOX

18.5.2022 15:51:04 CEST | Business Wire | Pressemeddelelse

Del
Behavox-forskning i kontinuerlig læring med på International Conference on Acoustics, Speech and Signal Processing (ICASSP)

Behavox , som udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører, fortæller i dag, at dens akademiske forskningsdokument om kunstig intelligens "kontinuerlig læring med lattice-fri MMI til stemmegenkendelse" er blevet accepteret af International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP er verdens største og mest omfattende tekniske konference med fokus på signalbehandling og tilhørende anvendelse. Behavox præsenterede den 9. maj 2022 dette dokument i Singapore for IEEE ICASSP 2022 .

"Nogle gange forsker videnskabsfolk for videnskabens skyld, og samfundet oplever ikke nogen umiddelbare fordele af forskningen. Vi har derimod skubbet videnskaben til en ny grænse for at finde en løsning på et aktuelt problem," siger Behavox's CTO Joseph Benjamin. "Vi er beærede over at have modtaget anerkendelse fra en så prestigefyldt konference og er meget stolte af vores team og det arbejde, folkene har udført."

Dokumentet, der er forfattet af Behavox's maskinlæringsteam, ser på udfordringerne i forbindelse med løbende forbedring af stemmegenkendelsessystemer i miljøer, der kræver beskyttelse af personoplysninger. Vores forskning har direkte forbindelse til Behavox's FoU-tilgang, der giver kunderne den bedste transskriptionskvalitet på det finansielle marked. I FinTech sker der hele tiden ændringer i det sprog og de data, som Behavox-systemerne hurtigt og pålideligt skal behandle, og stigningen i kryptovalutaer og videokommunikation er blot to eksempler.

Derfor skal maskinlæringsmodeller jævnligt opdateres med relevante data. For at gøre sådanne opdateringer mulige, uden at sætte databeskyttelsen over styr, skal modellen gradvist kunne forbedres i sikre klientmiljøer uden adgang til historiske data og data fra andre kunder. Dette er en alvorlig udfordring inden for maskinlæring på grund af den katastrofale glemsomhed, hvor modellen, efter at have forbedret en bestemt type data, begynder at præstere dårligt på tidligere lærte data.

ICASSP-dokumentet fra Behavox bidrager til den fortsatte læring til brug ved stemmegenkendelse. Forfatterne foreslår en ny algoritme, der udvider og forfiner den almindeligt anvendte LWF-teknik (Learning Without Forgetting), der er afhængig af en regulariseringsterm og tvinger neurale netværk til at mindske glemsomhed. Mere specifikt designede forfatterne en nyhed i form af neurale netværk med indlæring af tab på sekvensniveau, der kan bruges i stedet for den konventionelle, punktvise LWF. De viste en betydelig reduktion i glemsomhed, når man finjusterede det neurale netværk sekventielt efter forskellige accenter- og taleformer.

Behavox har konstateret, at brugen af stemmeplatforme med årene er steget 94 procent, og at næsten en tredjedel af al kommunikation på arbejdspladsen i gennemsnit foregår som telefonmøder eller videokonferencer.

Denne teknik er allerede blevet anvendt med succes på dets danske system, hvor samarbejdet mellem Behavox's lingvister, maskinlæringsteamet og en kunde gav Behavox mulighed for at opbygge sit første danske transskriptionssystem, der arbejder pålideligt med bankdata.

Om Behavox

Behovox udbyder en række sikkerhedsprodukter, der hjælper compliance-, HR- og sikkerhedsafdelingerne med at beskytte deres virksomhed og kolleger mod ondsindede aktører.

Med AI-baseret analyse af alle virksomhedens kommunikationsdata, herunder e-mail, chat, telefonmøde- og videokonferenceplatforme, hjælper Behavox virksomhederne med at identificere ulovlig, umoralsk og skadelig adfærd på arbejdspladsen.

Behavox, der blev grundlagt i 2014, har hovedkvarter i Montreal og kontorer i New York, London, Seattle, Singapore og Tokyo.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye